Kiora Pharmaceuticals, Inc. — Q3 2022 Form 10-Q Summary
Business Context and Reporting Period
Kiora is a clinical-stage specialty pharmaceutical company developing ophthalmic therapies. The report covers the three and nine months ended September 30, 2022, filed November 9, 2022. Key programs are KIO-301 for inherited and age-related retinal degeneration, KIO-101 for ocular inflammation associated with rheumatoid arthritis, and KIO-201 for persistent corneal epithelial defects and post-surgical corneal wounds.
Financial Results and Liquidity
- Revenue: The company has not generated significant revenue; no revenue was reported for the periods presented.
- Net loss: $5.119 million for Q3 2022 versus $3.035 million for Q3 2021; $11.085 million for the first nine months of 2022 versus $7.588 million in the comparable 2021 period.
- Operating expenses: $3.703 million in Q3 2022 versus $3.035 million in Q3 2021; $9.675 million for the first nine months versus $7.865 million in 2021.
- Research and development: $1.332 million in Q3 and $2.607 million year-to-date, compared with $1.628 million and $4.349 million, respectively, in 2021.
- General and administrative: $2.033 million in Q3 and $5.500 million year-to-date, compared with $1.339 million and $3.945 million, respectively, in 2021.
- Other expense: $1.416 million in Q3 and $1.411 million year-to-date, primarily reflecting the change in fair value of a warrant liability.
- Loss per share: $6.03 for Q3 and $22.06 for the first nine months, compared with $11.34 and $35.69, respectively, in 2021. Per-share figures were retroactively adjusted for the 1-for-40 reverse stock split.
- Cash flow: Net cash used in operating activities was $8.299 million for the first nine months of 2022 versus $7.756 million in 2021. Financing activities provided $5.378 million versus $17.795 million in 2021.
- Cash and liquidity: Cash and cash equivalents were $4.802 million at September 30, 2022; including restricted cash, total cash was $4.851 million, down from $7.900 million at December 31, 2021.
- Capitalization and obligations: Total liabilities were $7.141 million, including $3.653 million of contingent consideration and $0.136 million of operating lease liabilities. The filing does not report conventional debt balances.
- Margins: Operating and net margins are not meaningful because the company reported no significant revenue.
Material Changes Versus the Prior Comparable Period
- Q3 net loss increased by $2.085 million, primarily because of higher general and administrative expense and a $1.425 million warrant-liability fair-value expense.
- Year-to-date net loss increased by $3.497 million. General and administrative expense increased by $1.555 million, executive severance added $0.963 million, and contingent-consideration expense increased by $1.033 million.
- Year-to-date research and development expense decreased by $1.741 million, reflecting lower KIO-101, KIO-201, personnel, and research costs, partially offset by higher KIO-301 development costs.
- The company completed a July 2022 public offering generating approximately $5.297 million of net proceeds through common stock, Series E preferred stock, and warrants. The preferred stock was converted into 160,000 common shares in August.
- A 1-for-40 reverse stock split became effective September 27, 2022, reducing outstanding common shares from 43.163 million pre-split shares to 1.079 million post-split shares without changing authorized shares.
- In October 2022, a holder exercised Class A warrants for 65,000 common shares and $0.520 million of proceeds.
Outlook, Commentary, Risks and Unusual Items
- Clinical outlook: KIO-301 entered a Phase 1b trial in Q3 2022. Management expected to initiate a Phase 2 KIO-101 trial in Q4 2022, release topline KIO-201 PCED results in Q1 2023, and initiate a KIO-201 PRK Phase 3b study before the end of 2023.
- Funding outlook: Management estimated that cash on hand would fund planned operations into April 2023, subject to changes in spending. Additional equity, debt, licensing, collaboration, or government-grant funding will be required.
- Going concern: Recurring losses and negative operating cash flows created substantial doubt about the company’s ability to continue as a going concern. Management stated that additional financing may not be available on acceptable terms, or at all.
- Development risks: The pipeline remains in preclinical or clinical development and is subject to clinical-trial performance, regulatory approval, commercialization, manufacturing, competition, intellectual-property, and financing risks.
- Contingent consideration: The company may owe up to $18.799 million under acquisition-related milestone arrangements; the estimated fair value at September 30, 2022 was $3.653 million.
- Nasdaq compliance: The company regained compliance with the $1.00 minimum bid-price requirement on October 12, 2022 after the reverse stock split.
- Internal controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2022 because previously identified material weaknesses had not been remediated. Remediation efforts, including hiring finance personnel and consultants, remained ongoing.
- Payroll irregularity: The company identified an apparent June 2022 payroll irregularity involving approximately $0.120 million paid to unauthorized recipients. An independent investigation and review of internal controls were ongoing.
- COVID-19: The company continued to identify potential risks from supply-chain interruptions, facility closures, clinical-trial disruptions, and uncertain effects on liquidity and operations.
Important Facts for Investors to Verify
- Whether additional financing is obtained before the expected April 2023 liquidity horizon and on what terms.
- Progress, enrollment, safety, and results for the KIO-301, KIO-101, and KIO-201 clinical programs.
- Whether the identified internal-control material weaknesses and payroll irregularity investigation are fully resolved.
- The potential dilution from 1.663 million shares issuable under outstanding warrants, plus employee options and other equity awards.
- The timing and probability of acquisition-related milestone payments and the resulting cash requirements.
- Continued Nasdaq listing compliance and the effect of future equity offerings, warrant exercises, or other capital transactions on ownership dilution.